CervoMed to present on neflamapimod as DLB treatment at CTAD

CervoMed will deliver two oral presentations that inform on the potential of neflamapimod as a treatment for patients with dementia with Lewy bodies at the Clinical Trials on Alzheimer’s Disease Conference taking place October 29 – November 1, 2024, in Madrid, Spain. “We are delighted that both of our abstracts have been accepted as late-breaking oral presentations at this year’s CTAD,” said John Alam, MD, CEO of CervoMed. “This recognition by the conference scientific committee, whom we thank, reflects both the urgent need to address the impact of DLB on patients and their families and the importance of the ongoing RewinD-LB Phase 2b study to the dementia clinical research community. The baseline data from RewinD-LB demonstrates the disease burden at study entry is consistent with our expectations when we designed and powered the study. Additionally, the plasma biomarker data indicate that neflamapimod acts on the underlying disease process in DLB. Combined, the findings being reported in the two presentations increase our confidence in the RewinD-LB trial’s positive outcome. We look forward to reporting the topline data from RewinD-LB in December of this year.”